1 1 0 8 VOLUME 22 | NUMBER 10 | OCTOBER 2016 nAture medicine Cancer cells have a fundamental requirement for cellular building blocks, including nucleic acids, lipids and proteins, to support continuous proliferation 1 . To accommodate these chronic biosynthetic needs, cancer cells reprogram their metabolism, which has been denoted as one of the hallmarks of cancer 2 . Although many studies of tumor metabolism have focused on alterations in glucose and glutamine metabolism, a third well-described metabolic feature that has long been associated with tumor cells is elevated rates of de novo fatty acid synthesis (FASyn) 3-5 . The first committed step of FASyn is mediated by ACC-encoded by two related enzymes ACC1 (the product of the ACACA, or ACC1, gene) and ACC2 (the product of the ACACB, or ACC2, gene) in mammals-which catalyzes the ATPdependent carboxylation of acetyl-coenzyme A (acetyl-CoA) to form malonyl-CoA 6 . ACC1 is a cytoplasmic isoform that is thought to be the predominant isoform controlling FASyn, whereas ACC2 is tethered to the mitochondrial outer membrane, where localized malonyl-CoA production blocks carnitine palmitoyltransferase (CPT)-1 function to prevent fatty acids from entering the mitochondria to undergo fatty acid oxidation (FAOxn) 7 . The multidomain enzyme fatty acid synthase (FASN) uses malonyl-CoA and acetyl-CoA to catalyze subsequent successive reactions to form fatty acids, predominantly palmitate 5 . Subsequent elongation and desaturation reactions produce a milieu of fatty acids that cancer cells rely on for membrane formation, energy storage and production of signaling molecules 8 . Given that tumor cells rely on FASyn for these needs and that both ACACA (ACC1) and FASN mRNAs are upregulated in a number of cancers, FASyn has been postulated to offer a therapeutic window 3-5 . Correspondingly, efforts to target tumor cells that bear elevated rates of lipogenesis have focused on attempts to chemically inhibit either ACC or FASN 5 . This strategy, however, has been hampered by the lack of potent and specific compounds that show favorable drug-like properties in vivo. An alternative approach that has been used is to mimic a low-energy state in tumor cells, which results in an inhibition of FASyn through activation of a low-energy checkpoint that is mediated by the AMPactivated protein kinase (AMPK). AMPK is a serine-threonine kinase that directly inhibits ACC1 and ACC2 via phosphorylation of a highly conserved serine site near their amino terminus (mouse ACC1 Ser79; human ACC1 Ser117; mouse ACC2 Ser212; human ACC2 Ser222) 9 . Phosphorylation of this serine prevents dimerization of ACC, which is Continuous de novo fatty acid synthesis is a common feature of cancer that is required to meet the biosynthetic demands of a growing tumor. This process is controlled by the rate-limiting enzyme acetyl-CoA carboxylase (ACC), an attractive but traditionally intractable drug target. Here we provide genetic and pharmacological evidence that in preclinical models ACC is required to maintain the de novo fatty acid synthesis needed for growth and viability of non-small-cell lung cancer (NSCLC) cells. We describe the ability of ND-646-an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo. Chronic ND-646 treatment of xenograft and genetically engineered mouse models of NSCLC inhibited tumor growth. When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53 −/− (also known as KRAS p53) and Kras;Stk11 −/− (also known as KRAS Lkb1) mouse models of NSCLC. These findings demonstrate that ACC mediates a metabolic liability of NSCLC and that ACC inhibition by ND-646 is detrimental to NSCLC growth, supporting further examination of the use of ACC inhibitors in oncology.
required for activity, and under conditions of cellular energy deprivation, AMPK dominantly inhibits ACC activity 9 . AMPK is activated by the widely used drug metformin, mitochondrial poisons, nucleoside mimetics (such as the cell-permeable AMP analog AICAR) and smallmolecule synthetic AMPK activators, all of which have been shown to possess antilipogenic and anticancer properties [10] [11] [12] [13] [14] .
Short interfering RNA (siRNA)-mediated knockdown of ACC1 expression induces apoptosis in prostate 15 and breast 16 cancer cell lines, and chemical inhibition of ACC1 and ACC2 by the macrocyclic myxobacterial natural product soraphen A induces growth arrest and cytotoxicity in prostate cancer cells in vitro 17 . However, the clinical use of soraphen A is precluded by its teratogenicity in vivo and poor pharmacokinetic properties, and in spite of decades of pharmaceutical efforts to design orally bioavailable small-molecule inhibitors, ACC has remained an intractable target 18 . Here we characterize the function of ACC in NSCLC and describe the anticancer effects of ND-646, a small-molecule, orally bioavailable ACC inhibitor derived from our recently described series of allosteric ACC inhibitors 19 .
RESULTS

ACC1 activity maintains growth and viability of NSCLC cells
Despite differential subcellular localization and tissue-specific expression of ACC1 and ACC2, several studies suggest substantial redundancy between each isoform 14, 20, 21 . First, to examine the relative expression of ACC1 and ACC2 in NSCLC, we analyzed their mRNA expression levels in eight human NSCLC cell lines (A549, H157, H1355, A427, H23, H460, H358 and H1299) using RNA sequencing (RNA-seq). ACC1 was highly expressed in all eight NSCLC cell lines and was expressed at a substantially higher level than ACC2, which had expression levels ranging from low to undetectable (Fig. 1a) .
To investigate the function of ACC1 in NSCLC cells, we performed CRISPR-Cas9-mediated deletion of ACC1 in A549 and H157 cells ( Fig. 1b and Supplementary Fig. 1a ) and screened clones from each cell line for ACC1 deletion by immunoblotting. We used an antibody that recognizes both ACC1 and ACC2, as demonstrated by immunoblotting analyses of HEK293T cells transiently expressing each individual isoform (Supplementary Fig. 1b) . However, the deletion of ACC1 in A549 and H157 cells led to a complete loss of ACC detection using this antibody, further indicating that ACC2 protein expression is low in these cells ( Fig. 1b) . We isolated two ACC1-knockout (ACC1-KO) clones from A549 and H157 cells that showed complete loss of ACC1 protein expression and used two clones that had undergone selection for guide RNA (gRNA) transfection and Cas9 expression but lacked deletion of ACC1, and hence they expressed wild-type (WT) ACC1 ( Fig. 1b) We sequenced ACC2 in the ACC1-null clones to confirm the specificity of the gRNA and found that each ACC1-null clone retained wild-type alleles of ACC2. Stable expression of full-length human wild-type ACC1 cDNA in an ACC1-knockout clone (ACC1-KO#1 + ACC1) led to similar levels of ACC1 expression as the endogenous ACC1 protein (Fig. 1b) .
Growth and survival of the ACC1-KO clones were only possible by the exogenous addition of the fatty acid palmitate to the medium, suggesting that FASyn was impaired after ACC1 deletion. We therefore generated clones that were grown in the presence of exogenously added palmitate. To assess the effect of the ACC1 deletion on FASyn, we performed metabolic labeling in A549 and H157 clones with [U- 13 C 6 ]glucose for 24 h to measure carbon incorporation into newly synthesized fatty acids (FAs). ACC1 deletion led to a complete loss of FASyn in A549 and H157 cells, and we did not detect any newly synthesized palmitate, stearate or oleate in ACC1-null clones; stable ACC1 expression led to restoration of FASyn (Fig. 1c) . Therefore, ACC1 activity is required for FASyn in these NSCLC cells, and endogenous ACC2 is unable to compensate for the loss of ACC1 in these cells. However, we found that ACC2 overexpression in 293T ACC1-KO cells led to restoration of FASyn, similar to that seen with ACC1 overexpression, suggesting that ACC2 expression levels may dictate the ability of ACC2 to compensate for loss of ACC1 ( Supplementary Fig. 1c) .
To quantify the effect of ACC1 deletion on proliferation, we analyzed cellular growth of WT and ACC1-KO A549 and H157 clones that had been grown in palmitate and then plated into medium containing either regular fetal bovine serum (FBS) or delipidated FBS, in the presence or absence of exogenous palmitate. ACC1 deletion led to a significant decrease in cellular growth as compared to the WT controls in medium containing regular FBS, and this effect was even more pronounced in cells grown in delipidated FBS; however the growth phenotype was completely rescued by the addition of exogenous palmitate or the stable expression of ACC1 ( Fig. 1d and Supplementary Fig. 1d ). We generated two ACC2-KO A549 clones, which were identified by genomic ACC2 DNA sequencing, and found that ACC2 deletion had no effect on cellular proliferation (Supplementary Fig. 1e ). We also performed analogous CRISPR-Cas9 studies in a mouse NSCLC cell line (634T) 22 that is null for the expression of the tumor suppressor protein p53 (Trp53 −/− ) and contains a mutated allele of the oncogene Kras (Kras G12D/+ ), and we found that Acc1 deletion led to a proliferation defect and that Acc2 deletion had no effect (Supplementary Fig. 1f-h) .
Cellular viability was significantly decreased after ACC1 deletion in A549 and H157 clones (Fig. 1e) , and we found that ACC1-KO clones (g) Bioluminescence overlay images of subcutaneous growth of WT and ACC1-KO clones in nude mice (n = 5 mice per clone). Day 42 images were normalized to day 0 images. Colored scale shows photon flux in units of radiance (photons/s/cm 2 /steradian(sr)). Scale bars, 1 cm. (h) Tumor growth of A549 (left) and H157 (right) WT and ACC1-KO clones, represented as logarithmic fold change in photon flux during each imaging time point relative to day 0 (n = 10 tumors per clone). (i) Representative images of tumors (top) and average weight of all tumors (bottom) from A549 (left) or H157 (right) clones. Number in graph represents total number of tumors per genotype. Scale bars, 1 cm. For c-e, triplicate values were recorded, and data are shown from one of least two separate experiments. All values are expressed as means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; relative to WT (c;e;h, left;i, left) or to ACC1-KO (d;h, right;i, right) clones; as determined by two-way analysis of variance (ANOVA) (d,e,h) with Tukey's method for multiple-comparison test or by two-sided Student's t-test (c,i). For western blot analyses (b,f), actin was used as a loading control. npg had increased levels of caspase-cleaved poly(ADP-ribose) polymerase 1 (PARP1) in the absence of palmitate ( Fig. 1f) . Additionally, ACC1-KO clones expressed increased levels of C/EBP-homologous protein (CHOP), a transcription factor that regulates the unfolded protein response (UPR) and the expression of pro-apoptotic genes in response to endoplasmic reticulum (ER) stress 23 , consistent with previous observations with FASN inhibition in cancer cells 24 . Induction of cleaved PARP1 and expression of CHOP in ACC1-KO cells was rescued by addition of exogenous palmitate or stable expression of ACC1 cDNA ( Fig. 1f) .
Finally, to determine the effect of genetic ACC1 deletion on tumor growth, we injected 2 million WT and ACC1-KO tumor cells subcutaneously into the hind flanks of nude mice and performed bioluminescence imaging (BLI) for 42 d (A549) or 49 d (H157) ( Fig. 1g) . WT clones showed a 65-to 90-fold increase in bioluminescence during this period as compared to ACC1-KO clones, H157 H157 npg which either remained static or had a reduction in bioluminescence, suggesting a decrease in viability over time ( Fig. 1h) . WT clones developed larger, more vascularized tumors than ACC1-KO clones and had significantly increased tumor weights ( Fig. 1i) . Notably, stable expression of ACC1 cDNA rescued the tumor growth phenotype of H157 ACC1-KO tumors ( Fig. 1h,i) . Taken together, these data demonstrate the requirement for ACC1 activity to promote the FASyn that is needed for growth and survival of NSCLC cells in vitro and in vivo.
ND-646, an allosteric inhibitor of acetyl-CoA carboxylase
We recently described development of a series of allosteric ACC inhibitors, as exemplified by the highly liver-selective compound ND-630, which was designed for the treatment of fatty liver diseases, including non-alcoholic steatohepatitis (NASH) 19 . To determine whether pharmacological inhibition of ACC is therapeutic for NSCLC, we selected ND-646 from this series because of its broad tissue distribution. ND-646 ( Fig. 2a ) interacts with several residues within the dimerization site of the biotin carboxylase (BC) domain of ACC 19 , including Arg172 in ACC1 and Arg277 in ACC2, which are the same residues with which the AMPK-phosphorylated ACC serine peptides interact 25 (Fig. 2b) . ND-646 inhibits both ACC1 and ACC2 and therefore precludes the ability of ACC2 to compensate for ACC1 inhibition. In a manner analogous to that of soraphen A 26, 27 and ND-630 (ref. 19 ), ND-646 binding to the BC domain of ACC disrupts enzyme dimerization and inhibits enzymatic activity. ND-646 treatment inhibited dimerization of a recombinant human ACC2 BC domain (hACC2-BC) under native conditions; hACC2-BC migrated as a dimer in its absence and as a monomer in its presence (Supplementary Fig. 2a ).
In cell-free systems, ND-646 inhibited the enzymatic activity of recombinant human ACC1 (hACC1) with a half-maximal inhibitory concentration (IC 50 ) of 3.5 nM and of recombinant hACC2 with an IC 50 of 4.1 nM ( Supplementary Fig. 2b,c) . Pharmacokinetic analysis of ND-646 in male CD1 mice, a strain commonly used for nonclinical drug development, demonstrated a favorable drug-like profile of ND-646 ( Supplementary Fig. 2d ). For all subsequent analyses, we also used ND-608, a less active enantiomer of a closely related analog of ND-646 (hACC1 IC 50 = 4,790 nM; hACC2 IC 50 = 6,540 nM) as a negative control.
AMPK phosphorylation sites in ACC-a biomarker for ND-646 ND-646 interacts within the dimerization site of the BC domain of ACC, specifically binding to Arg172 in human ACC1 (hACC1 R172 ) and Arg277 in human ACC2 (hACC2 R277) ( Fig. 2b) , which is the same residue that the conserved AMPK-phosphorylated serines (p-Ser) in ACC1 and ACC2 bind to inhibit ACC activity 25, 28 . AMPK phosphorylation of these serines in the A-domain tail of ACC1 and ACC2 induces a conformational change of the tail to promote binding of p-Ser to arginine, which inhibits BC-domain dimerization and ACC enzymatic activity 25 , analogous to the effects of ND-646, suggesting that ND-646 and AMPK inhibit ACC via the same mechanism. Because ND-646 and p-Ser bind to the same arginine residue and ND-646 has a higher affinity for binding, ND-646 should prevent p-Ser from binding to this arginine. By using a phosphopeptide-specific antibody that recognizes the previously mentioned conserved AMPK phosphorylation sites in mouse and human ACC1 and ACC2 (hereafter referred to collectively as 'p-ACC'), we found that ND-646 treatment of A549 cells inhibited our ability to detect p-ACC at these AMPK phosphorylation sites npg ( Fig. 2c) . ND-646 treatment led to a complete loss of p-ACC detection in A549 cells without affecting total ACC protein levels at 24 h. These results were also recapitulated in vivo in livers and autochthonous (Kras G12D/+ ;Trp53 −/− ) lung tumors of mice that were dosed orally with a single dose of ND-646 (50 mg per kg body weight (mg/kg)) ( Fig. 2d,e ). To explain how ND-646 inhibits p-ACC detection, we tested several hypotheses. ND-646 did not prevent the ability of AMPK to phosphorylate Ser222 in the A-domain tail of recombinant hACC2-BC, despite inhibiting BC domain dimerization ( Supplementary Fig. 2e ). Additionally, ND-646 had no effect on the ability of AMPK to phosphorylate other direct substrates such as raptor, demonstrating that ND-646 does not inhibit AMPK activity ( Supplementary Fig. 2f ). Next, we reasoned that ND-646 might promote dephosphorylation of p-Ser, potentially explaining why ND-646 npg inhibits p-ACC detection. We found that cotreatment of A549 cells with ND-646 and the phosphatase inhibitor calyculin-A completely restored p-ACC detection (Fig. 2f) . Furthermore, mutation of the Arg172 binding site in human ACC1 to an alanine (hACC1 R172A ), which should prevent p-Ser from binding to arginine (analogous to ND-646 binding), led to overexpression of total ACC protein levels but an inability to detect p-ACC in ACC1-KO HEK293T cells ( Fig. 2g) . Calyculin A treatment completely restored p-ACC detection in hACC1 R172A -expressing cells, suggesting that the unbound p-Ser peptide in hACC1 R172A is constitutively dephosphorylated (Fig. 2g) . Additionally, the analogous hACC2 mutant (hACC2 R277A ) did not affect the ability of AMPK to phosphorylate hACC2-BC at Ser222 in vitro npg ( Supplementary Fig. 2g ). Taken together, these data suggest that ND-646 binding to the BC domain of ACC promotes its constitutive dephosphorylation by preventing the ability of the AMPK-phosphorylated p-Ser peptide to bind arginine, such that the p-Ser peptide is no longer protected from dephosphorylation. Notably, although dephosphorylation of ACC normally activates the enzyme, in the presence of ND-646, ACC activity remains inhibited, as ACC is unable to dimerize. These results support the mechanistic hypothesis that ND-646 inhibition of ACC activity mimics the physiological regulation of ACC function by AMPK. By modeling the crystal structure of ND-646 bound to hACC2-BC with prior crystal structures of the AMPK phosphorylation site 25 , we could visualize the effects of ND-646 binding to ACC that promote its inhibition and dephosphorylation ( Fig. 2h) .
Finally, to determine whether p-ACC status could be used to complement pharmacokinetic analysis of drug exposure in vivo, we treated athymic nude mice bearing A549 subcutaneous tumors with a single oral dose of 25 mg/kg ND-646. We measured the levels of ND-646 in tumor tissue and immunoblotted for p-ACC at the defined time points of 1 h and 8 h after dosing. Tumor exposure of ND-646 was high (~15 µM) at 1 h after dosing, which correlated with complete loss of p-ACC detection ( Supplementary Fig. 2h,i) . However, levels of ND-646 in tumors were significantly lower (~0.9 µM) 8 h after a single dose of ND-646, consistent with the short half-life of ND-646 in mice and the ability to detect p-ACC at this time point. These data demonstrate that the p-ACC biomarker correlates well with absolute levels of ND-646 exposure in tumors and suggest that multiple daily doses of ND-646 are optimal for ACC inhibition in vivo.
ND-646 inhibits FASyn in NSCLC cells in vitro
Given the pivotal role of ACC1 in regulating de novo FASyn, we performed metabolic labeling with [U- 13 C 6 ]glucose in ND-646treated A549 cells to measure FASyn (Fig. 3a) . Similar to the genetic npg deletion of ACC1 in A549 and H157 cells, ACC inhibition by ND-646 significantly inhibited the percentage of newly synthesized palmitate (C16:0), demonstrating that ND-646 promotes a near-complete shutdown of de novo FASyn (Fig. 3a) . Consistent with this, ND-646 treatment led to loss of Oil-Red-O staining of neutral lipids in A549 cells and a 90% decrease in total fatty acid content within 72 h (Fig. 3b) . Quantification of individual fatty acids revealed a marked reduction in the pools of a number of fatty acids, including the predominant saturated fatty acids palmitate and stearate, after ND-646 treatment (Fig. 3c) . ND-646 treatment of A549 cells did not significantly alter cholesterol synthesis, demonstrating that ACC inhibition does not affect acetyl-CoA utilization by non-FASyn pathways ( Supplementary  Fig. 3a) . Collectively, these metabolic tracing data demonstrate that-similar to the observations made after the genetic deletion of ACC1-ACC inhibition by ND-646 results in potent inhibition of FASyn and depletes cellular levels of fatty acids in NSCLC cells.
ND-646 inhibits proliferation and is cytotoxic in NSCLC cells ND-646 markedly inhibited proliferation (Supplementary Fig. 3b,c) and viability ( Supplementary Fig. 3d ) of A549, H157, H1355 and H460 NSCLC cells, demonstrating that ACC inhibition impairs cancer cell growth, consistent with results from the genetic deletion of ACC1 and consistent with previous studies 16, 17 . Additionally, the ability of ND-646 to inhibit proliferation was enhanced when cells were cultured in medium containing delipidated FBS (Fig. 3d) .
Notably, ND-646 treatment of ACC1-KO A549 and H157 clones grown in regular or delipidated FBS did not further affect cellular viability (Fig. 3e) , and cotreatment of A549 cells with ND-646 and palmitate restored viability and completely rescued the antiproliferative effects of ACC inhibition (Fig. 3f,g and Supplementary  Fig. 3e ). Palmitate-mediated rescue was also recapitulated in H460 cells (Supplementary Fig. 3f) , and palmitate had no effect on the ability of ND-646 to inhibit ACC because cotreatment with ND-646 resulted in loss of p-ACC detection, demonstrating that ACC is effectively inhibited in palmitate-rescued cells ( Supplementary  Fig. 3g ). These data demonstrate the specificity of ND-646 for ACC inhibition, as palmitate treatment would not be expected to rescue any unexpected off-target effects of ND-646.
ND-646 treatment of A549 cells led to induction of apoptosis ( Fig. 3h ) and ER stress (Supplementary Fig. 3h ). ACC inhibition led to increased phosphorylation of Ser51 on the α-subunit of eukaryotic translation initiation factor 2 (p-EIF2-α S51 ) and also increased the expression of CHOP. Cotreatment of A549 cells with ND-646 and palmitate completely rescued the effects of ND-646 on ER stress and apoptosis (Fig. 3i) . Taken together, these data suggest that the antiproliferative effects of ND-646 are due to inhibition of FASyn and depletion of cellular fatty acids
ND-646 inhibits FASyn and tumor growth in NSCLC xenografts
Our pharmacokinetic studies suggested that ND-646 would be more efficacious when delivered at multiple daily doses. Thus, to explore the effect of chronic ND-646 treatment on NSCLC tumor growth and to determine the efficacy of twice-daily dosing, we orally treated athymic nude mice bearing established A549 subcutaneous tumors with either vehicle twice daily (BID), 25 mg/kg ND-646 once daily (QD), 25 mg/kg ND-646 BID or 50 mg/kg ND-646 QD for 31 d (Fig. 4a) . ND-646 at 25 mg/kg QD was ineffective at inhibiting tumor growth; however, ND-646 administered at 25 mg/kg BID or 50 mg/kg QD significantly inhibited the growth of the subcutaneous A549 tumors (Fig. 4b,c) . ND-646 was well tolerated throughout the treatment period, with no significant weight loss occurring in the mice after chronic ND-646 dosing, suggesting that the maximum tolerated dose (MTD) had not been reached (Supplementary Fig. 4a ). Mice were euthanized at 1 h after administration of the final dose, and tissues were either prepared for immunohistochemistry (IHC) or immunoblot analysis. Tumors from mice that were treated with any dose of ND-646 lost detection of p-ACC at 1 h, demonstrating effective tumor penetration and acute ACC inhibition by ND-646 ( Fig. 4d and Supplementary Fig. 4b) . Notably, only for doses of ND-646 at which significant tumor growth inhibition was observed (25 mg/kg BID and 50 mg/kg QD) was there significant increase in p-EIF2-α S51 expression in tumor lysates ( Fig. 4d) , suggesting that p-EIF2-α S51 may be a therapeutic biomarker reflective of tumor growth inhibition and that p-ACC may be an ACC target-engagement biomarker in this setting. Supporting the anti-neoplastic properties of ND-646 at 25 mg/kg BID and 50 mg/kg QD in this model, tumors showed decreased Ki67 staining (Supplementary Fig. 4b,c) .
We were next interested in the effect of ND-646 on lung tumors growing in their native microenvironment in the lung. To determine whether ND-646 functionally inhibits FASyn in vivo, we administered deuterated water ( 2 H 2 O) to mice harboring A549 lung tumors to quantify deuterium incorporation into newly synthesized fatty acids in tumors as a measure of FASyn (Fig. 4e) . 2 H 2 O is incorporated into a number of biosynthetic intermediates that are required for fatty acid production, and it labels only fatty acids that are newly synthesized 29 . We injected luciferase-expressing A549 cells intravenously into immunocompromised SCID/beige mice to induce lung colonization and lung tumor growth. A549 lung tumors were grown for 42 d, and then mice were given 2 H 2 O (Online Methods) and simultaneously treated with either vehicle or ND-646 at 50 mg/kg BID for a period of 7 d (Fig. 4e) . After 7 d, mice were euthanized, and tumors were harvested and analyzed for FASyn. Deuterium enrichment in plasma H 2 O was similar between vehicle and ND-646 treated animals, and enrichment was sufficient to quantify FASyn ( Supplementary  Fig. 4d ). Next we measured the mass isotopologue distributions of npg total palmitate and stearate harvested from A549 tumors and calculated the fractional fatty acid synthesis (percentage of the total pool of palmitate and stearate that is synthesized during the labeling period) for each, as detailed in the Online Methods. Approximately 55% of the measured palmitate in vehicle-treated A549 lung tumors was newly synthesized during those 7 d, suggesting that A549 tumors are undergoing high rates of de novo FASyn (Fig. 4f) . Moreover, ND-646 treatment led to a significant reduction in the percentage of newly synthesized palmitate and stearate, demonstrating that FASyn is reduced by ND-646 in A549 lung tumors (Fig. 4f) . Although the above analysis calculates the fraction of total fatty acid pools within tumors that is newly synthesized, it does not take into account changes in molar pool sizes of these fatty acids. Thus, to determine maximal FASyn flux rates in tumors (assuming synthesis occurs entirely within npg the tumor, and turnover or oxidation is minimal) we calculated the molar amount of newly synthesized fatty acid per mg of tumor per day of 2 H 2 O labeling. Although this model assumes that the labeled pool of palmitate and stearate is newly synthesized, it is also possible that deuterium-labeled palmitate and stearate are also taken up from plasma and the surrounding microenvironment. Thus, we expressed this synthesis value as a maximal synthesis rate to account for sources outside of the tumor. We found that ND-646 treatment led to significant decreases in maximal FASyn rates of palmitate (60% reduction) and stearate (46% reduction) in A549 lung tumors (Fig. 4f) .
Next we examined the specific effect of chronic ND-646 treatment on the growth of A549 NSCLC lung tumors. Given that chronic ND-646 treatment was well tolerated at the doses used in our earlier studies, we opted to test the preclinical efficacy of ND-646 at 50 mg/kg BID and also a higher dose of 100 mg/kg BID. Additionally, we included carboplatin, which is a standard-of-care platinum analog used in NSCLC treatment, as a separate treatment group for direct comparison. A549 lung tumor growth was monitored, by bioluminescence imaging (BLI), for 3 weeks after intravenous injection, and then mice were randomized into their treatment groups and dosed chronically for a period of 6 weeks (Fig. 4g) . ND-646 was tolerated for the duration of the treatment period, and we noted a 10% decrease in the body weights of mice that were dosed with ND-646 at 50 mg/kg BID and 100 mg/kg BID, as compared to vehicle-treated mice (Supplementary Fig. 4e ). ND-646 treatment suppressed the growth of A549 lung tumors at 50 mg/kg BID and 100 mg/kg BID, as compared to vehicle treatment (Fig. 4h) . The tumors of vehicletreated mice showed a 60-fold increase in bioluminescence during the treatment period as compared to the tumors of mice treated with 50 mg/kg and 100 mg/kg ND-646, which increased by 33-fold and 23-fold, respectively (Supplementary Fig. 4f,g) . Next we prepared H&E-stained sections of formalin-fixed lungs to analyze histopathological changes in the A549 lung tumors (Supplementary Fig. 4h ). ND-646 treatment resulted in an 80% (50 mg/kg BID) and 82% (100 mg/kg BID) reduction in total lung tumor burden, as compared to that in vehicle-treated mice (Fig. 4i) , which was notably greater than the reduction in total lung tumor burden for carboplatin-treated mice (52%) in this dosing regimen. Morphometric analysis of tumor size revealed that ND-646 treatment resulted in a 47% (50 mg/kg BID) and 43% (100 mg/kg BID) reduction in average tumor size as compared to that for vehicle treatment (Supplementary Fig. 4i ). Quantification of 5-bromo-2′-deoxyuridine (BrdU) staining on lung sections, using advanced image analysis software (InForm-Perkin Elmer), revealed that ND-646 treatment resulted in a 39% (50 mg/kg BID) and 49% (100 mg/kg BID) decrease in the average number of BrdU + cells within each tumor (Supplementary Fig. 4j,k) . Additionally, IHC analysis for p-ACC confirmed loss of p-ACC detection in tumors from ND-646-treated mice (Supplementary Fig. 4j ). Taken together, these data demonstrate that ND-646 is detrimental to the growth of NSCLC tumors in preclinical lung xenograft models.
ND-646 inhibits tumor FASyn and growth in genetically engineered mouse models
Next we determined whether ND-646 inhibits FASyn in autochthonous lung tumors derived from the Kras LSLG12D ;Trp53 fl/fl ;R26 LSLluc (KP luc ) and Kras LSLG12D ;Stk11 fl/fl ;R26 LSLluc (KL luc ) genetically engineered mouse models of NSCLC 30 . In these models, adenovirusmediated Cre recombinase expression (Ad-Cre) in the lung epithelium (via intranasal instillation) induces oncogenic Kras G12D activation, which is coupled to deletion of either Trp53 (which encodes p53) or serine-threonine kinase 11 (Stk11; better known as Lkb1), as well as to expression of luciferase from the Rosa26 locus (R26 LSLluc ) in the same epithelial cell, resulting in lung tumor formation that can be monitored longitudinally by BLI. We initiated lung tumorigenesis in KP luc and KL luc mice and allowed lung tumors to form for 56 d; we then simultaneously administered 2 H 2 O and either vehicle BID or ND-646 at 50 mg/kg BID to mice for a period of 7 d (Online Methods). After 7 d, the mice were euthanized, and the lung tumors were harvested for analysis of FASyn (Fig. 5a) . Additionally, we harvested plasma to determine the effects of ND-646 on circulating plasma fatty acid levels. Deuterium enrichment analysis of plasma H 2 O demonstrated similar enrichment between the treatment groups and sufficient enrichment for FASyn analysis (Supplementary Fig. 5a ). Similar to that observed with A549 lung tumors, fractional synthesis of palmitate in lung tumors from vehicle-treated KP luc and KL luc mice was high, demonstrating that KP luc and KL luc lung tumors are undergoing high rates of de novo FASyn (Supplementary Fig. 5b) . Consistent with decreased fractional synthesis, ND-646 treatment of the mice led to a significant reduction in the maximal rate of palmitate and stearate synthesis in KP luc and KL luc lung tumors ( Fig. 5b) and also a significant reduction in the levels of total fatty acids ( Supplementary Fig. 5c,d) and free fatty acids (FFAs) (Fig. 5c,d and Supplementary Fig. 5e ) in the tumors. Finally, ND-646 treatment also significantly reduced the levels of a number of saturated and unsaturated FFAs in the plasma of KP luc and KL luc mice (Fig. 5e,f  and Supplementary Fig. 5f ).
Finally, we examined the effects of chronic ND-646 dosing on lung tumor growth in these mouse models. We induced lung tumors in KP luc and KL luc mice, let the tumors develop for 35 d and then randomized the mice into treatment groups, which consisted of either vehicle BID, ND-646 50 mg/kg or 100 mg/kg BID, carboplatin 25 mg/kg every 3 d, or a combination therapy of ND-646 50 mg/kg BID + carboplatin (Fig. 6a) . Mice were dosed chronically for a period of 6 weeks and monitored, by BLI, for lung tumor growth and response to therapy. We noted a 10% decrease in body weight in the KP luc and KL luc mice that were treated chronically with ND-646; however, body weights were maintained at that reduced level throughout the treatment period (Supplementary Fig. 6a) . A small subset of KP luc and KL luc mice that were dosed with ND-646 at 100 mg/kg BID developed a mild squinty eye phenotype starting after 4 weeks of treatment. We detected a reduction in lung tumor bioluminescence (photon flux) in KP luc and KL luc mice that were dosed with ND-646, relative to that in vehicle-treated mice (Fig. 6b,c and Supplementary  Fig. 6b) . Notably, BLI revealed that carboplatin treatment elicited a superior antitumor response in KL luc mice than in KP luc mice; however, treatment with the combination of ND-646 + carboplatin led to an improved response, as compared to monotherapy, in both models (Fig. 6b,c) . Treatment with the combination of ND-646 + carboplatin led to a larger decrease in body weight than monotherapy with either drug; however, body weights were maintained at that reduced level for the duration of the treatment period (Supplementary Fig. 6a) .
To assess the effects of ND-646 on lung tumorigenesis at the histological level, we prepared H&E-stained lung sections from every mouse in each treatment group (Fig. 6d,e ). ND-646 treatment led to a significant reduction in total tumor burden, as compared to that by vehicle treatment (Fig. 6f) . However, whereas the average tumor size was significantly reduced after ND-646 treatment in KP luc tumors, the reduction in KL luc tumors was much more modest (Fig. 6g) , demonstrating that, as a single agent, ND-646 has a greater effect on tumor size in tumors from KP luc mice than in tumors from KL luc mice.
npg By binning KP luc and KL luc lung tumors into six size ranges, we found that ND-646 treatment suppressed the outgrowth of large tumors in KP luc mice, an effect that was not apparent in KL luc mice, which lacked large tumors in general (Fig. 6h) , demonstrating that ACC inhibition prevents the outgrowth of large KP luc tumors. Of note, carboplatin treatment led to a reduction in total tumor burden in both KL luc and KP luc mice, although it was less effective than ND-646 treatment in any of the conditions tested, except against KL luc tumors ( Supplementary  Fig. 6c ). Carboplatin treatment induced nuclear p53 accumulation in KL luc tumors, suggesting that the enhanced efficacy of the drug observed in KL luc tumors might occur through a p53-dependent mechanism to suppress growth (Supplementary Fig. 6d) .
Treatment with the combination of ND-646 + carboplatin led to a marked antitumor response in both KP luc and KL luc tumors ( Fig. 6d-g) . BrdU quantification revealed a significant reduction in BrdU positivity of tumors that were treated with ND-646 singly or in combination with carboplatin in KP luc and KL luc mice ( Fig. 6i and  Supplementary Fig. 6e ). As expected, ND-646 treatment also led to loss of p-ACC detection in tumors (Supplementary Fig. 6e ). Finally, ND-646 treatment resulted in a significant reduction in a number of saturated and unsaturated fatty acids in the liver and plasma after 6 weeks ( Supplementary Fig. 6f,g) .
DISCUSSION
The requirement for FASyn is a potential metabolic liability for tumor growth that might be exploited for cancer therapy 5 . The results from our deuterium-labeling experiments support a model in which lung tumors are undergoing high rates of de novo FASyn, and our study is the first to show that pharmacological inhibition of ACC, the ratelimiting enzyme required for de novo FASyn, results in robust inhibition of tumor growth in biologically relevant models of NSCLC. Thus, this work supports a critical role of ACC to maintain de novo FASyn to support lung tumor growth. In contrast, a prior study suggested a tumor suppressor function for ACC in some contexts 31 ; however, the majority of previous studies support a role for ACC in promoting tumor growth and survival [15] [16] [17] 32 . Here we found that CRISPR-Cas9-mediated deletion of ACC1 in human NSCLC cells led to complete loss of FASyn accompanied by loss of proliferation, viability and tumorigenic potential. Systemic inhibition of ACC via the broadly distributed, orally bioavailable inhibitor ND-646 blocked tumor growth and suppressed FASyn in xenografts and genetically engineered autochthonous lung tumors.
Future studies are needed to obtain a deeper understanding of the extent to which distinct oncogenic lesions and other genetic factors modulate sensitivity to ACC inhibitors. In addition, although increased FAOxn itself has been implicated as a metabolic liability in oncology 33 , the effects of simultaneous inhibition of FASyn and activation of FAOxn have not been studied as a therapeutic strategy for cancer therapy. Given that ND-646 is an allosteric inhibitor of ACC1 and ACC2, ND-646 treatment by itself would be expected to inhibit FASyn and promote FAOxn; however, the tumor cell lines used in our study express little to no endogenous ACC2. Studies examining the effect of ND-646 in tumor cells expressing high levels of both ACC isoforms will contribute to our understanding of the role that ACC2 plays in tumorigenesis. In this context, the ability of ND-646 to prevent the relative redundancy observed between the ACC isoforms will be an important feature.
Chronic ND-646 treatment of mice was generally well tolerated in our study. The mild squinty eye phenotype we observed occurred in only a small subset of mice at the highest dose of ND-646 after 4 weeks of chronic dosing. Given the ability of ND-646 to inhibit FASyn in a number of tissues, including lowering plasma levels of fatty acids that might contribute to the antitumor effects of ND-646, ACC inhibition may also favorably affect the morbidity and mortality associated with a number of metabolic diseases, including diabetes, obesity and fatty liver disease 19 . Given the unique mechanism of action of our ACC inhibitors, the p-ACC-specific antibody biomarker described in this report may facilitate the additional discovery of potent small molecules that interact with this region of the enzyme and may aid in determining ACC inhibition and therapeutic response in a clinical setting. Future understanding of mechanisms that dictate sensitivity and requirement of most cancer cells for elevated FASyn remains an interesting area for study, as does strategic and rationale design of combination therapies to enhance the efficacy of ACC inhibition. In summary, our data with ND-646 warrant the further evaluation of ACC inhibitors for cancer to define the therapeutic conditions in which ACC inhibitors will find maximal clinical utility.
METHODS
Methods and any associated references are available in the online version of the paper.
For tumor-prevention studies, mice were treated intranasally with Ad-Cre and imaged bi-weekly using BLI. At 35 d post inhalation, mice underwent BLI and were assigned into their treatment groups based on similar average photon flux (photons/s) in the region of interest encompassing the thoracic cavity. Mice were excluded from future study if they failed to develop bioluminescent tumors at day 35. Mice were dosed chronically for 6 weeks and were subject to procedures identical to those for the i.v. studies mentioned previously. 9-14 mice were used per treatment, and they were monitored for lung tumor growth by BLI every 2 weeks.
For all BLI, d-luciferin (150 mg/kg) was administered by i.p. injection to mice for 10 min before imaging. For all mouse BID dosing, the time between doses was approximately 8 h. Baseline body weights were recorded at the initiation of treatment and were recorded daily throughout the treatment period. Mice were also monitored for potential adverse events and for general health status during the course of the study. Power calculations were not used to determine sample size of mice. Sample size was chosen based on available litter sizes or previously established studies that sufficiently accounted for variability among animals to determine a preclinical effect. For statistical analysis, variances were similar between all treatment groups.
Post hoc analyses from tumor sections. For A549 lung xenograft and GEMM studies, tumor size per treatment was calculated by measuring each individual tumor size from H&E-stained sections using morphometric analysis in Panoramic viewer software (3D Histech). To quantitate lung tumor area, individual tumor sizes were summed for each mouse from each treatment, and the percentage of tumor encompassing total lung area was calculated per mouse per treatment. Total lung area was quantified using Panoramic viewer software. 40, 41 . 5 µL of sample or standard was reacted with 4 µL of 10N NaOH and 4 µL of a 5% (vol/vol) solution of acetone in acetonitrile for 24 h. Acetone was extracted by the addition of 600 µL chloroform and 0.5 g Na 2 SO 4 , followed by vigorous mixing. 100 µL of the chloroform was then transferred to a GC/MS vial. Acetone was measured using an Agilent DB-35MS column (30 m × 0.25 mm i.d. × 0.25 mm; Agilent J&W Scientific) installed in an Agilent 7890A gas chromatograph (GC) interfaced with an Agilent 5975C mass spectrometer (MS) with the following temperature program: 60 °C initial, increase by 20 °C/min to 100 °C, increase by 50 °C/min to 220 °C, and hold for 1 min. The split ratio was 40:1 with a helium flow of 1 mL/min. Acetone eluted at approximately 1.5 min. The mass spectrometer was operated in the electron-impact mode (70 eV). The abundance of mass ions 58-64 was quantified and corrected for natural abundance. Up to six deuterium atoms can transfer to acetone depending on 2 H 2 O enrichment; thus, the molepercent enrichment was quantified and compared to a ten-point standard curve to quantify plasma 2 H 2 O enrichment.
Deuterated water ( 2 H 2 O) in vivo
Total fatty acids were extracted from tissues and plasma using a Bligh and Dyer-based methanol-chloroform-water extraction method with [U-2 H 31 ] C16:0 (d31-C16:0) as an internal standard. Briefly, 500 µL methanol, 500 µL chloroform, 200 µL H 2 O and 10 µL 10 mM d31-C16:0 per 10 mg tissue were added to weighed pre-ground tissue. This was vortexed for 10 min followed by centrifugation at 10,000g for 5 min. The lower chloroform phase was dried and then derivatized to form fatty acid methyl esters (FAMEs) via addition of 500 µL 2% H 2 SO 4 and incubation at 50 °C for 2 h. FAMEs were extracted via addition of 100 µL saturated salt solution and 500 µL hexane, and these were analyzed using a Select FAME column (100 m × 0.25 mm i.d.) installed in an Aglient 7890A GC interfaced with an Agilent 5975C MS.
Calculations. The mass isotopomer distributions of each fatty acid was determined and corrected for natural abundance using in-house algorithms adapted from Fernandez (1996) 37 . Calculation of the fraction of newly synthesized fatty acids (FNS) was based on the method described by Lee et al. 29 , in which FNS is described by the following equation: FNS = ME/(n × p), where ME is the average number of deuterium atoms incorporated per molecule (ME = 1 × m 1 + 2 × m 2 + 3 × m 3 …), p is the deuterium enrichment in water, and n is the maximum number of hydrogen atoms from water incorporated per molecule. N was determined using the equation: m 2 /m 1 = ((N -1)/2) × p/q as described by Lee et al. 42 , where q is the fraction of hydrogen atoms and p + q = 1. Fractional synthesis rates (FSRs) were calculated by the following equation: FSR = FNS × (n FA /t), where n FA represents the molar amount of each fatty acid, and t is the time for which 2 H 2 O was administered.
FFA analysis. Extracted samples were dissolved in 100 µL CHCl 3 ; 15 µL was injected for analysis. LC separation was achieved using a Bio-Bond 5U C4 column (Dikma). The LC solvents were as follows: buffer A, 95:5 H 2 O:methanol + 0.03% NH 4 OH; buffer B, 60:35:5 isopropanol:methanol:H 2 O + 0.03% NH 4 OH. A typical LC run consisted of the following for 70 min after injection: 0.1 mL/min 100% buffer A for 5 min, 0.4 mL/min linear gradient from 20% buffer B to 100% buffer B over 50 min, 0.5 mL/min 100% buffer B for 8 min and equilibration with 0.5 mL/min 100% buffer A for 7 min. FFA analysis was performed using a Thermo Scientific Q Exactive Plus fitted with a heated electrospray ionization source. The MS source parameters were 4 kV spray voltage, with a probe temperature of 437.5 °C and capillary temperature of 268.75 °C. Full-scan MS data was collected with a resolution of 70 k, AGC target 1 × 10 6 , maximum (max) injection time of 100 ms and a scan range of 150-2,000 m/z. Data-dependent MS (top 5 mode) was acquired with a resolution of 35 k, AGC target 1 × 10 5 , max injection time of 50 ms, isolation window 1 m/z, scan range 200 to 2,000 m/z, stepped normalized collision energy (NCE) of 20, 30 and 40. Extracted ion chromatograms for each FFA were generated using a m/z ± 0.01 mass window around the calculated exact mass (i.e., palmitic acid, calculated exact mass for M-H is 255.2330, and the extracted ion chromatogram was 255. 22-255.24 ). Quantification of the FFAs was performed by measuring the area under the peak and dividing this number by the area under the peak for [ 13 C 16 ]palmitate. The ratio of FFA/[ 13 C 16 ]palmitate was then multiplied by 200 pmol (the concentration of the [ 13 C 16 ]palmitate) and divided by the tumor weight or plasma volume to afford the molar concentration per unit mass or unit volume.
Immunohistochemistry and image analysis. Formalin-fixed tumors were transferred into 70% ethanol after 18 h and paraffin-embedded (FFPE) at the Salk Institute Histology Core. 5-µm sections from FFPE tissues were prepared and stained with hematoxylin and eosin. For immunohistochemistry, slides were deparaffinized and rehydrated. Antigen retrieval was performed with citrate buffer (11 min at high heat for p-ACC, 30 min at high heat for BrdU). Endogenous peroxidase activity was quenched with hydrogen peroxide. Using the ImmPress HRP Ig (Peroxidase) Polymer Detection Kits (Vector Labs), slides were blocked and incubated overnight with primary antibody diluted in blocking buffer, and secondary antibody steps were carried out, according to the manufacturer's instructions. Staining was visualized using ImmPACT DAB Peroxidase Substrate (Vector Labs, SK-4105). Slides were counterstained with hematoxylin, dehydrated and mounted with Cytoseal 60 (Thermo Scientific). Primary antibodies used were specific to the following proteins: p-ACC(Ser79) (Cell Signaling Technology, #11818, 1:400), BrdU (Abcam, #6326, 1:200) and p53 (clone CM5 1:200, Novocastra). Immunostained slides were scanned using a Perkin Elmer Slide Scanner (Panoramic MIDI Digital Slide Scanner). Inform v2.1 image analysis software (Cambridge Research and Instrumentation) was used as a nonbiased method to quantify BrdU and p53 staining. Briefly, for each region analyzed, hematoxylin-stained nuclei were identified by the software and tallied to generate a total cell count per tumor. Nuclei were also analyzed for diaminobenzidine (DAB) staining and were, correspondingly, binned as negative or positive for BrdU, or binned by staining intensity on a 4-bin scale for p53. A ratio between the number of DAB-positive and total nuclei was used to calculate the percentage of cells staining positive for BrdU or those within different staining intensity categories for p53 per tumor. Quantitative analysis was performed on individually cropped tumors from all mice per treatment group for BrdU and a subset of mice for vehicle, carboplatin or ND-646 + carboplatin treatment for p53. For BrdU, the percentage of BrdU-positive cells was then determined for each tumor and plotted. For p53, the nuclear staining intensity was plotted for each treatment. For analysis, npg investigators were blinded to the treatment condition by random assignment of mouse numbers that were naive to the investigators.
Additional methodology is described in Supplementary Note 1.
Statistical analyses. Statistical analyses are described in each figure and were performed using GraphPad Prism 7. For statistical test selection, distribution fitting and variance testing was determined to justify test selection. The majority of the data had similar variance, and all data met the assumptions of the statistical test. For all statistical analyses, significance was accepted at the 95% confidence level.
